<DOC>
	<DOCNO>NCT01323400</DOCNO>
	<brief_summary>The purpose study evaluate antitumor activity pazopanib patient metastatic and/or locally advance unresectable Gastrointestinal Stromal Tumors ( GIST ) resistant imatinib sunitinib . This phase II , randomize , multicentre study .</brief_summary>
	<brief_title>Efficacy Pazopanib Gastrointestinal Stromal Tumors ( GIST )</brief_title>
	<detailed_description>Complete resection , without associate anticancer therapy , standard treatment GIST . Even though prognosis advance GIST tremendously improve introduction tyrosine kinase inhibitor ( TKI-imatinib , sunitinib ... ) , vast majority patient develop secondary resistance agent . The therapeutic option patient advanced GIST resistance ( intolerance ) imatinib sunitinib remain limited . Some new molecule currently evaluate patient metastatic locally advanced - imatinib-resistant disease . Nilotinib , instance , evaluate phase I/II trial compassionate use program median progression-free survival ( PFS ) close 3 month median overall survival close 8.5 month . A phase III trial compare nilotinib vs. best supportive care ( BSC ) +/- imatinib sunitinib ( investigator choice ) complete result pending . Another molecule , Sorafenib , evaluate 4th line treatment compassionate use study , median PFS close 5 month median overall survival 10-13 month . There currently recognize standard option failure 2nd line treatment , recently update guideline NCCN ESMO ( 2009 ) suggest possible reintroduction TKI attempt control progression sensitive cell clone . Pazopanib broad spectrum TKI target KIT , PDGFR VEGFR test phase II trial advance sarcomas demonstrate promising antitumor activity . Whether pazopanib would useful patient GIST know . In present study , propose analyze antitumor activity pazopanib patient GIST refractory imatinib sunitinib . The drug test BSC randomize setting , possible crossing-over no-treatment arm .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . Histologically confirm , unresectable , metastatic and/or locally advanced GIST . 3 . Progression intolerance treatment least imatinib ( 400 mg 600/800 mg/d ) sunitinib either 50mg/d 4w/6w schedule 37.5mg/d continuous dose . Intolerance define document grade 3 high toxicity require treatment interruption document patient record . 4 . Measurable disease accord RECIST v1.1 . 5 . Performance status ≤ 2 ( WHO ) . 6 . Left Ventricular Ejection Fraction ( LVEF ) accordance local standard . 7 . Adequate organ system function define : Haematologic parameter Absolute neutrophil count ( ANC ) ≥ 1.5 G/L Haemoglobin ≥ 9 g/dL Platelets ≥ 100 G/L Prothrombin time ( PT ) international normalize ratio ( INR ) ≤ 1.2 X upper limit normal ( ULN ) NB : Subjects receive anticoagulation therapy eligible INR stable within recommended range . Partial thromboplastin time ( PTT ) ≤ 1.2 X ULN Hepatic parameter Total bilirubin ≤ 1.5 X ULN AST ALT ≤ 2.5 X ULN Renal parameter Serum creatinine ≤ 1.5 mg/dL ( 133 µmol/L ) , great 1.5 mg/dL : calculated creatinine clearance ≥ 50 mL/min Urine Protein Creatinine ratio ( UPC ) &lt; 1 . If UPC ≥ 1 , subject must 24hour urine protein value &lt; 1g eligible . Biochemical parameter Kaliemia ≥ 1 X low limit normal ( LLN ) 8. ) Females nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) . b ) Females childbearing potential provide pregnant lactating , include female negative serum pregnancy test within 2 week prior first dose study treatment , preferably close first dose possible , agree use adequate contraception . 9 . Affiliation health insurance company . 10 . Subjects must provide write informed consent 1 . Prior malignant disease ( GIST ) within 3 year prior entry , exception situ breast cell carcinoma situ carcinoma cervix basocellular carcinoma spinocellular carcinoma bladder neoplasm , treat least 6 month evidence relapse . 2 . History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except patient previouslytreated CNS metastasis , asymptomatic requirement steroid antiseizure medication 6 month prior first dose study drug . CNS screen compute tomography [ CT ] magnetic resonance image [ MRI ] require clinically indicated subject history CNS metastases . 3 . Treatment follow anticancer therapy : radiation therapy , surgery tumour embolisation within 14 day prior first dose pazopanib OR chemotherapy , biological therapy investigational therapy within 14 day five halflives drug ( whichever longer ) prior first dose pazopanib . The analgesic radiation therapy allow ( irradiated lesion wo n't choose target lesion evaluation ) 4 . Any ongoing toxicity prior anticancer therapy &gt; Grade 1 follow and/or progressing severity , except alopecia . 5 . Other uncontrolled severe medical condition . 6 . Presence uncontrolled infection . 7 . Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding . may affect absorption investigational product . 8 . Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥ 140 mmHg diastolic blood pressure ( DBP ) ≥ 90 mmHg ] . NB : Initiation adjustment antihypertensive medication ( ) permit prior study entry . BP must reassess two occasion &gt; 1 hour interval ; occasion , mean ( 3 reading ) SBP / DBP value BP assessment must &lt; 140/90 mmHg subject eligible study . 9 . History cardiovascular pathology within past 6 month . 10 . Corrected QT interval ( QTcB ) &gt; 480 msec use Bazett 's formula . 11 . History cerebrovascular accident , include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) , within past 6 month . NB : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week inclusion eligible . 12 . Major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture ulcer ( procedure catheter placement consider major ) . 13 . Evidence active bleeding bleed diathesis . 14 . Haemoptysis within 8 week inclusion . 15 . Platelet transfusion past 7 day . 16 . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel . 17 . Concomitant bilirubin AST/ALT elevation ULN . 18 . Treatment antivitamin K ( LMWH allow ) . 19 . Inability unwillingness discontinue prohibit medication least 14 day five halflives drug ( whichever longer ) prior first dose study drug duration study . 20 . Inability swallow . 21 . Pregnant lactate woman 22 . Impossibility comply protocol constraint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>GIST</keyword>
	<keyword>Resistant</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
	<keyword>Best supportive care</keyword>
	<keyword>Progression-free survival</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Objective response rate</keyword>
	<keyword>Best response</keyword>
	<keyword>Tolerance profile</keyword>
</DOC>